Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study.
Takeshi OsonoiAtsuko TamasawaYusuke OsonoiKensuke OfuchiMakoto KatohMiyoko SaitoPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)
Mitsubishi Tanabe Pharma Corporation.